FDA Inspection
Chartwell Pharmaceuticals LLCChartwell Pharmaceuticals LLC – FDA Inspection, May 24, 2023
Record Details
This FDA Inspection record concerns Chartwell Pharmaceuticals LLC, with an inspection on May 24, 2023, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · 477cac0d-4d79-4668-bd49-e0a78e758ada
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1206056
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
6- 21 CFR 211.111Establishment of time limitations
- 21 CFR 211.166(b)Adequate number of batches on stability
- 21 CFR 211.22(d)Procedures not in writing, fully followed
- 21 CFR 211.25(a)Training--operations, GMPs, written procedures
- 21 CFR 211.42(a)Buildings of Suitable Size, Construction, Location
- 21 CFR 211.63Equipment Design, Size and Location
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Chartwell Pharmaceuticals LLC
8| Date | Classification | Office | Project area |
|---|---|---|---|
| November 18, 2025 | OAI | New York District Office | Drug Quality Assurance |
| December 19, 2024 | Not classified | New York District Office | Drug Quality Assurance |
| May 31, 2024 | OAI | New York District Office | Generic Drug Evaluation |
| April 8, 2024 | VAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| September 26, 2018 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Chartwell Pharmaceuticals LLC
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.